Coya Therapeutics, Inc.
COYA
$4.48
-$0.07-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 251.10K | 3.96M | 3.56M | 163.60K | 257.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 251.10K | 3.96M | 3.56M | 163.60K | 257.90K |
| Cost of Revenue | 4.10M | 4.94M | 2.92M | 3.66M | 5.21M |
| Gross Profit | -3.59M | -980.50K | 647.40K | -3.50M | -4.96M |
| SG&A Expenses | 3.78M | 3.27M | 2.56M | 2.91M | 2.71M |
| Depreciation & Amortization | 2.80K | 6.80K | 6.80K | 6.80K | 6.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.88M | 8.22M | 5.48M | 6.58M | 7.93M |
| Operating Income | -7.63M | -4.26M | -1.92M | -6.41M | -7.68M |
| Income Before Tax | -7.21M | -5.71M | -2.12M | -6.10M | -7.31M |
| Income Tax Expenses | -- | 3.10K | -- | -- | -- |
| Earnings from Continuing Operations | -7.21M | -5.71M | -2.12M | -6.10M | -7.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.21M | -5.71M | -2.12M | -6.10M | -7.31M |
| EBIT | -7.63M | -4.26M | -1.92M | -6.41M | -7.68M |
| EBITDA | -7.63M | -4.25M | -1.91M | -6.41M | -7.67M |
| EPS Basic | -0.32 | -0.34 | -0.13 | -0.36 | -0.44 |
| Normalized Basic EPS | -0.20 | -0.15 | -0.06 | -0.23 | -0.27 |
| EPS Diluted | -0.64 | -0.34 | -0.13 | -0.36 | -0.44 |
| Normalized Diluted EPS | -0.20 | -0.15 | -0.06 | -0.23 | -0.27 |
| Average Basic Shares Outstanding | 22.64M | 16.74M | 16.73M | 16.73M | 16.72M |
| Average Diluted Shares Outstanding | 22.64M | 16.74M | 16.73M | 16.73M | 16.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |